SERPING1 and hereditary angioedema: This trial will augment the existing evidence from phase 1 and 2 trials, which demonstrated that sebetralstat had favorable pharmacokinetics and pharmacodynamics, was generally safe and well tolerated, and led to rapid symptom relief in patients with HAE‐C1‐INH.19, 25, 26 Due to novel additions to the phase 2 trial design, KONFIDENT will provide a broader understanding of the efficacy and safety of sebetralstat for the on‐demand treatment of attacks in patients with HAE‐C1‐INH.